KAI1/CD82在肾母细胞瘤转移中的表达及意义

The expression and significance of KAI1/CD82 in the metastasis of nephroblastoma

目的探讨KAI1/CD82在肾母细胞瘤转移中的表达及临床意义。方法选取38例确诊为肾母细胞瘤的组织蜡块标本,按有无转移分为两组,采用免疫组织化学的方法检测其KAI1/CD82的表达。结果肾母细胞瘤中无转移组和有淋巴结或远处转移组的KAI1/CD82阳性表达率分别为53.85%、33.33%,两者间的差异有统计学意义;Ⅰ、Ⅱ、Ⅲ、Ⅳ期肾母细胞瘤中KAI1/CD82阳性表达率分别为62.50%、58.33%、33.33%、33.33%,各组间的差异无统计学意义。化疗组与未化疗组间差异均无统计学意义。结论肾母细胞瘤中KAI1/CD82的阳性表达率与肿瘤是否转移有关,与临床分期无关。

Objective To discuss the expression and clinical significance of KAI1/CD82 in the metastasis of nephroblastoma. Methods In the tissues - embedded specimens from 38 cases of nephroblastoma diagnosed pathologically, the expression of KAI1/CD82 was detected by immunohistochemistry. Results The positive rate of the expression of KAI1/CD82 in nephroblastoma with or without metastasis was 53.85 % and 33.33 %, respectively （ P 〈 0.05）. The positive rate of KAI1/CD82 in nephroblastoma of stages Ⅰ , Ⅱ , Ⅲ and Ⅳ stages was 62.50% ,58.33% ,33.33% and 33.33% respectively （P 〉 0.05）. There was no significant difference in the expression of KAI1/CD82 between chemotherapy and non - chemotherapy groups （ P 〉 0.05）. Conclusion The positive rate of KAI1/ CD82 in nephroblastoma is related with metastasis, but not with clinical stage.